Almaabdi Kholoud, Ahmad Zareen, Johnson Sindhu R
Toronto Scleroderma Program, Division of Rheumatology, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON M5T 1R8, Canada.
Toronto Scleroderma Program, Schroeder Arthritis Institute, Division of Rheumatology, Department of Medicine, Toronto Western Hospital, Toronto, ON M5T 379, Canada.
Diagnostics (Basel). 2023 Feb 23;13(5):851. doi: 10.3390/diagnostics13050851.
Systemic sclerosis is a systemic autoimmune rheumatic disease characterized by immune abnormalities, leading to vasculopathy and fibrosis. Autoantibody testing has become an increasingly important part of diagnosis and prognostication. Clinicians have been limited to antinuclear antibody (ANA), antitopoisomerase I (also known as anti-Scl-70) antibody, and anticentromere antibody testing. Many clinicians now have improved access to an expanded profile of autoantibody testing. In this narrative review article, we review the epidemiology, clinical associations, and prognostic value of advanced autoantibody testing in people with systemic sclerosis.
系统性硬化症是一种系统性自身免疫性风湿性疾病，其特征为免疫异常，可导致血管病变和纤维化。自身抗体检测已成为诊断和预后评估中日益重要的一部分。临床医生以往仅限于检测抗核抗体（ANA）、抗拓扑异构酶I（也称为抗Scl-70）抗体和抗着丝粒抗体。现在，许多临床医生能够更方便地进行更广泛的自身抗体检测。在这篇叙述性综述文章中，我们回顾了系统性硬化症患者进行先进自身抗体检测的流行病学、临床关联及预后价值。
